// App-Quantinova.ai

6011 : Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).

Researchers

Presenter

  • Joshua Bauml

Principal Investigators

  • Tanguy Y. Seiwert

  • David G. Pfister

  • Francis P. Worden

  • Stephen V. Liu

  • Jill Gilbert

  • Nabil F. Saba

  • Jared Weiss

  • Lori J. Wirth

  • Ammar Sukari

  • Hyunseok Kang

  • Michael K. Gibson

  • Erminia Massarelli

  • Steven Francis Powell

  • Amy Meister

  • Xinxin Shu

  • Jonathan D. Cheng

  • Robert I. Haddad

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • The University of Chicago Medical Center, Chicago, IL

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Georgetown University, Washington, DC

  • Vanderbilt University School of Medicine, Nashville, TN

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Massachusetts General Hospital, Boston, MA

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • University Hospitals Case Medical Center, Cleveland, OH

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Sanford Health, Sioux Falls, SD

  • Merck & Co., Inc., Kenilworth, NJ

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Erbitux

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02255097

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved